Clinical Trials Browser

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline × capivasertib × Clear all

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline